FDA clears Revi Extend implant for urgency urinary incontinence

The FDA has granted 510(k) clearance to Revi Extend, a long-term, minimally invasive, implantable tibial neuromodulation therapy for urgency urinary incontinence, the device’s manufacturer, BlueWind Medical, announced.“FDA clearance of our next-generation implant reflects our continued commitment to meaningful innovation for patients and physicians,” Kerry Nelson, BlueWind